

Ref. No.: WOCK/SEC/SE/2025-26/028

8th August, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Press Release

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025.

A copy of the same will also be uploaded on the Company's website www.wockhardt.com

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary

Encls: as above

Mumbai, August 8th, 2025

Wockhardt: Q1 FY26 Highlights

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st Quarter Results for Financial Year 2025-26, today.

 **INR 738 Cr.**
Revenue

 **INR 101 Cr.**
EBITDA

Revenue for Q1FY26 is INR 738 Cr compared to INR 747 Cr in the previous year. QoQ growth of 1% in EBITDA in Q1FY26, EBITDA for Q1FY26 of INR 101 Cr compared to INR 100 Cr in the previous year.

Business approach of the Company is to continue the growth momentum with focus on profitability while balancing investments in innovative portfolio comprising Novel Antibiotics and Diabetes Biosimilars to build an organization across various aspects of regulatory, clinical, medical and commercial excellence for pre-launch and launch activities in India and developed markets.

Novel Antibiotics:

ZAYNICH® (Zidebactam/Cefepime, WCK 5222) Filed for approval in India and pre-NDA submission meetings completed with US FDA



Zaynich is manufactured and supplied from US FDA approved third party manufacturing sites in Europe for USA and developed markets.

The following two trials have been completed with remarkable clinical efficacy;

1. Global, pivotal, registration-enabling, Phase III study in hospitalized complicated urinary tract infection (cUTI) patients and
2. Trial in patients with meropenem-resistant infections in India.

Two pre-NDA meetings with US FDA have been successfully completed and the filing of the New Drug Application (NDA) dossier is targeted in September 2025. In India, the NDA has already been submitted on March 31, 2025.


Leading U.K. Medical Journal publishes a Complex Case of Severe Pan-drug Resistant Infection in U.S. Liver Transplant Patient Successfully Treated with Zaynich®

The Zaynich® continues to demonstrate its life-saving attributes under compassionate use. One of such case was recently published by a top-notch British medical journal- Journal of Antimicrobial Chemotherapy –AMR, describes ability of Zaynich® in rescuing a US patient.




The publications have been jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins. Likewise, in an another publication in Journal of Global Antimicrobial Resistance, a case series comprising of 5 Bone and Joint Infections patients successfully treated with Zaynich® has been published by clinicians from Christian Medical College, Vellore. These patients were treated with Zaynich® for 4-6 weeks.

MIQNAF® NAFITHROMYCIN, approved and launched on May 27 2025, in India



prescribing realizing the clinical value of the antibiotic.

Following the launch of Miqnaf®, initial response from clinicians across India has been very encouraging. Within few weeks of its launch the prescriptions have reached >1000 and several doctors are now repetitively



EMROK/ EMROK O:

A land mark publication in a reputed UK medical journal – Journal of Antimicrobial Resistance – AMR has published a nearly untreatable case of bone and joint infections caused by one of the toughest pathogen – Burkholderia pseudomallei. Initial treatment with two most commonly used antibiotic, trimethoprim/sulfamethoxazole and ceftazidime failed as the patient turned allergic to both. With no treatment option, Emrok emerged as the salvage therapy for this patient, achieving clinical improvement without relapse with > 8 months of therapy. Notably, even after more than 6 months after completing the therapy, the patient remained infection-free. This first reported use of Emrok in melioidosis underscores its potential as a valuable drug option in such complex infections.

**EMROK
EMROK-O****>100,000****PATIENTS TREATED****ERTAPENEM-ZIDEACTAM (WCK 6777):**

A Phase 2 study protocol is under development comparing once-a-day WCK 6777 with a leading novel three-times-a-day antibiotic for the treatment of resistant infection. This study would help identify clinical dose for Phase 3 study. US FDA has recently granted a Fast-track designation to WCK 6777 for two indications – cUTI and cIAI.

FAST TRACK DESIGNATION**WCK 6777****USFDA****ONCE-A-DAY
β-Lactam Enhancer****FOVISCU (WCK 4282):**


Phase 3 study of WCK 4282 is slated to be completed in FY 25-26. This study compared WCK 4282 with leading hospital antibiotic meropenem. The results of this study would form the basis for filing NDA. The clinical data of Phase 3 study would position WCK 4282 as effective drug for the treatment of highly prevalent ESBL infections for which current treatment options - piperacillin/tazobactam and cefoperazone/sulbactam have been compromised due to rising resistance.

Strategic Realignment of US Operations to Focus on Innovative Portfolio

As part of our ongoing strategic transformation, Wockhardt has completed a planned exit from its US generics business to eliminate recurring losses and enable sharper focus on innovation-led growth. This move aligns with our global priorities and unlocks capital and management

bandwidth to accelerate progress in our differentiated antibiotic discovery and insulin biologics portfolios—key pillars of our future-ready business model.

Business Highlights



India Business stood at Rs.178 crore in Q1FY26 with a growth of 8% compared to the previous year.

UK Business stood at Rs.312 crore in Q1FY26 with a growth of 13% compared to the previous year.

Irish Business stood at Rs.50 crore in Q1FY26 with a growth of 11% compared to the previous year.

New Products Launch:

- 1 Filing and 4 Launches in Wockhardt UK and Pinewood
- Biosimilars & NCE - 6 Filings & 6 Approvals
- EMROK/ EMROK O- Registration has been filed in 9 countries of ROW and other markets
- Approval received for EMROK O for Uganda

Intellectual Property Update:

- 5 patents were filed during the quarter ended 30th June 2025 and the cumulative filings till date are 3278.
- The company was granted 5 patents during the quarter and now holds 853 patents.

PATENTS

Filings till Date : 3278

Patents held : 853

Financial Performance:

Particulars	Q1 FY26	Q1 FY25	Q4 FY25
	Apr - Jun 2025	Apr - Jun 2024	Jan - Mar 2025
Total Revenue	738	747	743
EBITDA before R&D	128	127	113
EBITDA % to Sales	17.4%	16.9%	15.2%
R&D	27	27	34
R&D % to Sales	3.7%	3.6%	4.6%
EBITDA	101	100	79
EBITDA Margins %	13.7%	13.4%	10.7%
Exceptional Items #	(97)	-	-
PBT	(109)	(6)	(22)
Profit After Tax	(108)	(16)	(45)
PAT Margins %	-14.6%	-2.1%	-6.1%

Exceptional Items: Goodwill impaired as Morton Grove Pharmaceuticals Inc., a step down subsidiary of Wockhardt, entered voluntary liquidation proceedings under Chapter 7 of the US Bankruptcy Code, effective July 11, 2025

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.



Wockhardt is employing around ~2900 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 76% of its global revenues coming from international businesses.